OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer

OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Cash runway extended through 2026, beyond September 30, 2026 sunset date for rare pediatric priority review ...